Random-Forest-Algorithm-Based Applications of the Basic Characteristics and Serum and Imaging Biomarkers to Diagnose Mild Cognitive Impairment

Page: [76 - 83] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Background: Mild cognitive impairment (MCI) is considered the early stage of Alzheimer's Disease (AD). The purpose of our study was to analyze the basic characteristics and serum and imaging biomarkers for the diagnosis of MCI patients as a more objective and accurate approach.

Methods: The Montreal Cognitive Test was used to test 119 patients aged ≥65. Such serum biomarkers were detected as preprandial blood glucose, triglyceride, total cholesterol, Aβ1-40, Aβ1-42, and P-tau. All the subjects were scanned with 1.5T MRI (GE Healthcare, WI, USA) to obtain DWI, DTI, and ASL images. DTI was used to calculate the anisotropy fraction (FA), DWI was used to calculate the apparent diffusion coefficient (ADC), and ASL was used to calculate the cerebral blood flow (CBF). All the images were then registered to the SPACE of the Montreal Neurological Institute (MNI). In 116 brain regions, the medians of FA, ADC, and CBF were extracted by automatic anatomical labeling. The basic characteristics included gender, education level, and previous disease history of hypertension, diabetes, and coronary heart disease. The data were randomly divided into training sets and test ones. The recursive random forest algorithm was applied to the diagnosis of MCI patients, and the recursive feature elimination (RFE) method was used to screen the significant basic features and serum and imaging biomarkers. The overall accuracy, sensitivity, and specificity were calculated, respectively, and so were the ROC curve and the area under the curve (AUC) of the test set.

Results: When the variable of the MCI diagnostic model was an imaging biomarker, the training accuracy of the random forest was 100%, the correct rate of the test was 86.23%, the sensitivity was 78.26%, and the specificity was 100%. When combining the basic characteristics, the serum and imaging biomarkers as variables of the MCI diagnostic model, the training accuracy of the random forest was found to be 100%; the test accuracy was 97.23%, the sensitivity was 94.44%, and the specificity was 100%. RFE analysis showed that age, Aβ1-40, and cerebellum_4_6 were the most important basic feature, serum biomarker, imaging biomarker, respectively.

Conclusion: Imaging biomarkers can effectively diagnose MCI. The diagnostic capacity of the basic trait biomarkers or serum biomarkers for MCI is limited, but their combination with imaging biomarkers can improve the diagnostic capacity, as indicated by the sensitivity of 94.44% and the specificity of 100% in our model. As a machine learning method, a random forest can help diagnose MCI effectively while screening important influencing factors.

Keywords: Machine learning, algorithms, cognitive dysfunction, diagnostic tool, mild cognitive impairment, screening.

[1]
Farina FR, Pragulbickaitė G, Bennett M, et al. Contralateral Delay Activity is not a robust marker of cognitive function in older adults at risk of Mild Cognitive Impairment. Eur J Neurosci 2020; 51(12): 2367-75.
[http://dx.doi.org/10.1111/ejn.14652] [PMID: 31856354]
[2]
Galasko D, Xiao M, Xu D, et al. Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer’s disease. Alzheimers Dement (N Y) 2019; 5(1): 871-82.
[http://dx.doi.org/10.1016/j.trci.2019.11.002] [PMID: 31853477]
[3]
Hao X, Bao Y, Guo Y, et al. Multi-modal neuroimaging feature selection with consistent metric constraint for diagnosis of Alzheimer’s disease. Med Image Anal 2020; 60: 101625.
[http://dx.doi.org/10.1016/j.media.2019.101625] [PMID: 31841947]
[4]
Knezevic D, Mizrahi R. Molecular imaging of neuroinflammation in Alzheimer's disease and mild cognitive impairment. Prog Neuropsychopharmacol Biol Psychiatry 2018; 80(Pt B): 123-31.
[http://dx.doi.org/10.1016/j.pnpbp.2017.05.007] [PMID: 28533150]
[5]
Shen T, Li Y, Wu P, Zuo C, Yan Z. Decision supporting model for one-year conversion probability from MCI to AD using CNN and SVM. Annu Int Conf IEEE Eng Med Biol Soc 2018; 2018: 738-41.
[http://dx.doi.org/10.1109/EMBC.2018.8512398] [PMID: 30440502]
[6]
Wang T, Xiao S, Chen K, et al. Prevalence, incidence, risk and protective factors of amnestic mild cognitive impairment in the elderly in Shanghai. Curr Alzheimer Res 2017; 14(4): 460-6.
[http://dx.doi.org/10.2174/1567205013666161122094208] [PMID: 27875948]
[7]
Hernandez JV. Prevalence of mild cognitive impairment and dementia in a population of adults over 60 years old in el salvador. J Alzheimer’s Assoc 2017; 13(7): 842.
[http://dx.doi.org/10.1016/j.jalz.2017.06.1183]
[8]
Wong MYZ, Tan CS, Venketasubramanian N, et al. Prevalence and risk factors for cognitive impairment and dementia in Indians: A multiethnic perspective from a singaporean study. J Alzheimers Dis 2019; 71(1): 341-51.
[http://dx.doi.org/10.3233/JAD-190610] [PMID: 31381520]
[9]
Miyake Y, Tanaka K, Senba H, et al. Hearing impairment and prevalence of mild cognitive impairment in Japan: Baseline data from the aidai cohort study in Yawatahama and Uchiko. Ear Hear 2020; 41(2): 254-8.
[http://dx.doi.org/10.1097/AUD.0000000000000773] [PMID: 31356389]
[10]
Sanford AM. Mild cognitive impairment. Clin Geriatr Med 2017; 33(3): 325-37.
[http://dx.doi.org/10.1016/j.cger.2017.02.005] [PMID: 28689566]
[11]
Raj V, Opie M, Arnold AC. Cognitive and psychological issues in postural tachycardia syndrome. Auton Neurosci 2018; 215: 46-55.
[http://dx.doi.org/10.1016/j.autneu.2018.03.004] [PMID: 29628432]
[12]
Crawford TJ, Taylor S, Mardanbegi D, et al. The effects of previous error and success in Alzheimer’s disease and mild cognitive impairment. Sci Rep 2019; 9(1): 20204.
[http://dx.doi.org/10.1038/s41598-019-56625-2] [PMID: 31882919]
[13]
Perrotte M, Haddad M, Le Page A, Frost EH, Fulöp T, Ramassamy C. Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer’s disease. Neurobiol Aging 2020; 86: 102-11.
[http://dx.doi.org/10.1016/j.neurobiolaging.2019.10.010] [PMID: 31883770]
[14]
Soldan A, Pettigrew C, Zhu Y, et al. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease. Neurology 2020; 94(9): e950-60.
[http://dx.doi.org/10.1212/WNL.0000000000008864] [PMID: 31888969]
[15]
Chiti A, Cecchi P, Pesaresi I, et al. Functional magnetic resonance imaging with encoding task in patients with mild cognitive impairment and different severity of leukoaraiosis. Psychiatry Res Neuroimaging 2018; 282: 126-31.
[http://dx.doi.org/10.1016/j.pscychresns.2018.06.012] [PMID: 30539733]
[16]
Marmarelis VZ, Shin DC, Tarumi T, Zhang R. Comparing model-based cerebrovascular physiomarkers with DTI biomarkers in MCI patients. Brain Behav 2019; 9(8): e01356.
[http://dx.doi.org/10.1002/brb3.1356] [PMID: 31286695]
[17]
Gyebnár G, Szabó Á, Sirály E, et al. What can DTI tell about early cognitive impairment? - Differentiation between MCI subtypes and healthy controls by diffusion tensor imaging. Psychiatry Res Neuroimaging 2018; 272: 46-57.
[http://dx.doi.org/10.1016/j.pscychresns.2017.10.007] [PMID: 29126669]
[18]
Lo Buono V, Palmeri R, Corallo F, et al. Diffusion tensor imaging of white matter degeneration in early stage of Alzheimer’s disease: A review. Int J Neurosci 2020; 130(3): 243-50.
[http://dx.doi.org/10.1080/00207454.2019.1667798] [PMID: 31549530]
[19]
Tu MC, Lo CP, Huang CF, Huang WH, Deng JF, Hsu YH. Visual attention performances and related cerebral microstructural integrity among subjects with subjective cognitive decline and mild cognitive impairment. Front Aging Neurosci 2018; 10: 268.
[http://dx.doi.org/10.3389/fnagi.2018.00268] [PMID: 30245626]
[20]
Ray KM, Wang H, Chu Y, et al. Mild cognitive impairment: Apparent diffusion coefficient in regional gray matter and white matter structures. Radiology 2006; 241(1): 197-205.
[http://dx.doi.org/10.1148/radiol.2411051051] [PMID: 16990677]
[21]
Nir TM, Jahanshad N, Toga AW, et al. Connectivity network measures predict volumetric atrophy in mild cognitive impairment. Neurobiol Aging 2015; 36(1): S113-20.
[http://dx.doi.org/10.1016/j.neurobiolaging.2014.04.038] [PMID: 25444606]
[22]
Kim CM, Alvarado RL, Stephens K, et al. Associations between cerebral blood flow and structural and functional brain imaging measures in individuals with neuropsychologically defined mild cognitive impairment. Neurobiol Aging 2020; 86: 64-74.
[http://dx.doi.org/10.1016/j.neurobiolaging.2019.10.023] [PMID: 31813626]
[23]
Daianu M, Jahanshad N, Nir TM, et al. Rich club analysis in the Alzheimer’s disease connectome reveals a relatively undisturbed structural core network. Hum Brain Mapp 2015; 36(8): 3087-103.
[http://dx.doi.org/10.1002/hbm.22830] [PMID: 26037224]
[24]
Liu Y, Zhong X, Shen J, et al. Elevated serum TC and LDL-C levels in Alzheimer’s disease and mild cognitive impairment: A meta-analysis study. Brain Res 2020; 1727: 146554.
[http://dx.doi.org/10.1016/j.brainres.2019.146554] [PMID: 31765631]
[25]
Bahrami A, Barreto GE, Lombardi G, Pirro M, Sahebkar A. Emerging roles for high-density lipoproteins in neurodegenerative disorders. Biofactors 2019; 45(5): 725-39.
[http://dx.doi.org/10.1002/biof.1541] [PMID: 31301192]
[26]
Jiang Y, Zhu Z, Shi J, et al. Metabolomics in the development and progression of dementia: A systematic review. Front Neurosci 2019; 13: 343.
[http://dx.doi.org/10.3389/fnins.2019.00343] [PMID: 31031585]
[27]
Koch M, DeKosky ST, Goodman M, et al. High-density lipoprotein and its apolipoprotein-defined subspecies and risk of dementia. J Lipid Res 2020; 61(3): 445-54.
[http://dx.doi.org/10.1194/jlr.P119000473] [PMID: 31892526]
[28]
Jayaraj RL, Azimullah S, Beiram R. Diabetes as a risk factor for Alzheimer’s disease in the Middle East and its shared pathological mediators. Saudi J Biol Sci 2020; 27(2): 736-50.
[http://dx.doi.org/10.1016/j.sjbs.2019.12.028] [PMID: 32210695]
[29]
Carbonell F, Zijdenbos AP, Bedell BJ. Spatially distributed amyloid-β reduces glucose metabolism in mild cognitive impairment. J Alzheimers Dis 2020; 73(2): 543-57.
[http://dx.doi.org/10.3233/JAD-190560] [PMID: 31796668]
[30]
Nebel RA, Aggarwal NT, Barnes LL, et al. Understanding the impact of sex and gender in Alzheimer’s disease: A call to action. Alzheimers Dement 2018; 14(9): 1171-83.
[http://dx.doi.org/10.1016/j.jalz.2018.04.008] [PMID: 29907423]
[31]
Ibrahim A, Singh DKA, Shahar S. ‘Timed Up and Go’ test: Age, gender and cognitive impairment stratified normative values of older adults. PLoS One 2017; 12(10): e0185641.
[http://dx.doi.org/10.1371/journal.pone.0185641] [PMID: 28972994]
[32]
Ramanan VK, Castillo AM, Knopman DS, et al. Association of apolipoprotein E ɛ4, educational level, and sex with Tau deposition and tau-mediated metabolic dysfunction in older adults. JAMA Netw Open 2019; 2(10): e1913909.
[http://dx.doi.org/10.1001/jamanetworkopen.2019.13909] [PMID: 31642932]
[33]
Liu A, Sun Z, McDade EM, Hughes TF, Ganguli M, Chang CH. Blood pressure and memory: Novel approaches to modeling nonlinear effects in longitudinal studies. Alzheimer Dis Assoc Disord 2019; 33(4): 291-8.
[http://dx.doi.org/10.1097/WAD.0000000000000346] [PMID: 31567145]
[34]
Carson N, Leach L, Murphy KJ. A re-examination of Montreal Cognitive Assessment (MoCA) cutoff scores. Int J Geriatr Psychiatry 2018; 33(2): 379-88.
[http://dx.doi.org/10.1002/gps.4756] [PMID: 28731508]
[35]
Avants BB, Epstein CL, Grossman M, Gee JC. Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain. Med Image Anal 2008; 12(1): 26-41.
[http://dx.doi.org/10.1016/j.media.2007.06.004] [PMID: 17659998]
[36]
Rolls ET, Joliot M, Tzourio-Mazoyer N. Implementation of a new parcellation of the orbitofrontal cortex in the automated anatomical labeling atlas. Neuroimage 2015; 122: 1-5.
[http://dx.doi.org/10.1016/j.neuroimage.2015.07.075] [PMID: 26241684]
[37]
Deng W, Zhang K, Busov V, Wei H. Recursive random forest algorithm for constructing multilayered hierarchical gene regulatory networks that govern biological pathways. PLoS One 2017; 12(2): e0171532.
[http://dx.doi.org/10.1371/journal.pone.0171532] [PMID: 28158291]
[38]
Guo L, Wang Z, Du Y, et al. Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma. Cancer Cell Int 2020; 20(1): 251.
[http://dx.doi.org/10.1186/s12935-020-01274-z] [PMID: 32565735]
[39]
Fu J, Liu Q, Du Y, et al. Age- and sex-specific prevalence and modifiable risk factors of mild cognitive impairment among older adults in China: A population-based observational study. Front Aging Neurosci 2020; 12: 578742.
[http://dx.doi.org/10.3389/fnagi.2020.578742] [PMID: 33192471]
[40]
Qin H, Zhu B, Hu C, Zhao X. Later-onset hypertension is associated with higher risk of dementia in mild cognitive impairment. Front Neurol 2020; 11: 557977.
[http://dx.doi.org/10.3389/fneur.2020.557977] [PMID: 33324316]
[41]
Maccora J, Peters R, Anstey KJ. What does (low) education mean in terms of dementia risk? A systematic review and meta-analysis highlighting inconsistency in measuring and operationalising education. SSM Popul Health 2020; 12: 100654.
[http://dx.doi.org/10.1016/j.ssmph.2020.100654] [PMID: 33313373]
[42]
Xia C, Vonder M, Sidorenkov G, et al. The relationship of coronary artery calcium and clinical coronary artery disease with cognitive function: A systematic review and meta-analysis. J Atheroscler Thromb 2020; 27(9): 934-58.
[http://dx.doi.org/10.5551/jat.52928] [PMID: 32062643]
[43]
Nam E, Lee YB, Moon C, Chang KA. Serum tau proteins as potential biomarkers for the assessment of Alzheimer’s disease progression. Int J Mol Sci 2020; 21(14): E5007.
[http://dx.doi.org/10.3390/ijms21145007] [PMID: 32679907]
[44]
Abe K, Shang J, Shi X, et al. A new serum biomarker set to detect mild cognitive impairment and Alzheimer’s disease by peptidome technology. J Alzheimers Dis 2020; 73(1): 217-27.
[http://dx.doi.org/10.3233/JAD-191016] [PMID: 31771070]
[45]
McFarlane O, Kozakiewicz M, Kędziora-Kornatowska K, et al. Blood lipids and cognitive performance of aging polish adults: A case-control study based on the PolSenior project. Front Aging Neurosci 2020; 12: 590546.
[http://dx.doi.org/10.3389/fnagi.2020.590546] [PMID: 33328967]
[46]
Li Y, Liang Y, Tan X, et al. Altered functional hubs and connectivity in type 2 diabetes mellitus without mild cognitive impairment. Front Neurol 2020; 11: 1016.
[http://dx.doi.org/10.3389/fneur.2020.01016] [PMID: 33071928]
[47]
Yan S, Zheng C, Cui B, et al. Multiparametric imaging hippocampal neurodegeneration and functional connectivity with simultaneous PET/MRI in Alzheimer’s disease. Eur J Nucl Med Mol Imaging 2020; 47(10): 2440-52.
[http://dx.doi.org/10.1007/s00259-020-04752-8] [PMID: 32157432]
[48]
An N, Fu Y, Shi J, et al. Synergistic effects of APOE and CLU may increase the risk of Alzheimer’s disease: Acceleration of atrophy in the volumes and shapes of the Hippocampus and Amygdala. J Alzheimers Dis 2021; 80(3): 1311-27.
[http://dx.doi.org/10.3233/JAD-201162] [PMID: 33682707]